Wynnewood-based OCMS Bio, a new life sciences startup, believes it has found a better way to produce monoclonal antibodies by using technology that makes cells glow developed by Dr. Scott Dessain at the Lankenau Institute for Medical Research, writes John George for the Philadelphia Business Journal.
The biotech company has entered into a licensing deal with the research division of Main Line Health for the technology that improves on the historical process of developing monoclonal antibodies.
Until now, researchers had to clone thousands of cells before then examining them one-by-one for a certain trait.
The new technology however, incorporates fluorescence to isolate and light up those cells that produce antibodies carrying the desired characteristics for diagnosing or treating a specific disease.
Dessain, who is a professor and director of the Center for Human Antibody Technology at LIMR, is also the chief scientific officer at OCMS Bio.
His On-Cell mAb screening technology platform can now be used to rapidly identify and isolate B cells with desired antibodies.
“We are excited to make Dr. Dessain’s breakthroughs available to the biotechnology community,” said Martina Molsbergen, OCMS Bio chief commercial officer.
Read more about OCMS Bio at the Philadelphia Business Journal by clicking here.
[uam_ad id=”64837″]
